IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report)'s share price rose 1.4% during trading on Tuesday . The stock traded as high as $1.45 and last traded at $1.45. Approximately 149,348 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 284,299 shares. The stock had previously closed at $1.43.
Analyst Ratings Changes
IOBT has been the topic of several research reports. Piper Sandler upgraded shares of IO Biotech to a "strong-buy" rating in a research report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating on shares of IO Biotech in a research report on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of IO Biotech to a "sell" rating in a research report on Saturday, June 14th.
Check Out Our Latest Report on IO Biotech
IO Biotech Stock Performance
The company has a 50 day simple moving average of $1.28 and a two-hundred day simple moving average of $1.05. The company has a market cap of $94.87 million, a PE ratio of -0.97 and a beta of 0.36.
Institutional Investors Weigh In On IO Biotech
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of IO Biotech during the first quarter worth approximately $26,000. XTX Topco Ltd acquired a new position in shares of IO Biotech in the fourth quarter valued at $26,000. Renaissance Technologies LLC raised its stake in shares of IO Biotech by 22.5% in the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after purchasing an additional 21,800 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of IO Biotech in the fourth quarter valued at $249,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of IO Biotech in the fourth quarter valued at $407,000. 54.76% of the stock is currently owned by institutional investors and hedge funds.
IO Biotech Company Profile
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Read More
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
